Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome

Abdullahi Dandare; Muhammad Jawad Khan; Aisha Naeem; Afrose Liaquat

doi:10.1016/j.gendis.2022.05.022

您当前的位置：

首页 >

文章列表页 >

Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome

Review Articles | 更新时间：2024-02-04

- Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome
- Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome
- Genes & Diseases 2023年1卷第6期页码：2393-2413
- 作者机构：
  
  1. Department of Biosciences, COMSATS University Islamabad,Islamabad,Pakistan,45550
  2. Department of Biochemistry, Usmanu Danfodiyo University, Sokoto,Nigeria,840104
  3. Ministry of Public Health, POB42, Doha,Qatar
  4. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,, DC,Washington,USA,20057
  5. Shifa College of Medicine, Shifa Tameer-E-Millat University,Islamabad,Pakistan,45550
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.05.022
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-11-1，
扫描看全文
Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome[J]. Genes & Diseases, 2023,1(6):2393-2413.

Abdullahi Dandare, Muhammad Jawad Khan, Aisha Naeem, et al. Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome[J]. Genes & Diseases, 2023,1(6):2393-2413.
Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome[J]. Genes & Diseases, 2023,1(6):2393-2413. DOI： 10.1016/j.gendis.2022.05.022.

Abdullahi Dandare, Muhammad Jawad Khan, Aisha Naeem, et al. Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome[J]. Genes & Diseases, 2023,1(6):2393-2413. DOI： 10.1016/j.gendis.2022.05.022.

摘要

Abstract

Non-coding RNAs (ncRNAs) participate in the regulation of several cellular processes including transcription

RNA processing and genome rearrangement. The aberrant expression of ncRNAs is associated with several pathological conditions. In this review

we focused on recent information to elucidate the role of various regulatory ncRNAs i.e.

micro RNAs (miRNAs)

circular RNAs (circRNAs) and long-chain non-coding RNAs (lncRNAs)

in metabolic diseases

e.g.

obesity

diabetes mellitus (DM)

cardiovascular diseases (CVD) and metabolic syndrome (MetS). The mechanisms by which ncRNAs participated in disease pathophysiology were also highlighted. miRNAs regulate the expression of genes at transcriptional and translational levels. circRNAs modulate the regulation of gene expression via miRNA sponging activity

interacting with RNA binding protein and polymerase II transcription regulation. lncRNAs regulate the expression of genes by acting as a protein decoy

miRNA sponging

miRNA host gene

binding to miRNA response elements (MRE) and the recruitment of transcriptional element or chromatin modifiers. We examined the role of ncRNAs in the disease pathogenesis and their potential role as molecular markers for diagnosis

prognosis and therapeutic targets. We showed the involvement of ncRNAs in the onset of obesity and its progression to MetS and CVD. miRNA-192

miRNA-122

and miRNA-221 were dysregulated in all these metabolic diseases. Other ncRNAs

implicated in at least three diseases include miRNA-15a

miRNA-26

miRNA-27a

miRNA-320

and miRNA-375. Dysregulation of ncRNAs increased the risk of development of DM and MetS and its progression to CVD in obese individuals. Hence

these molecules are potential targets to arrest or delay the progression of metabolic diseases.

关键词

Keywords

BiomarkersCircRNAslncRNAsMetabolic diseasesmiRNAsNon-coding RNAsTherapeutic targets

references

1 A.S. Bayoumi, T. Aonuma, J.P. Teoh, Y.L. Tang, I.M. KimCircular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases Acta Pharmacol Sin, 39 (7) (2018), pp. 1100-1109

2 W. Hou, H.L. BonkovskyNon-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy World J Gastroenterol, 19 (44) (2013), pp. 7836-7845

3 H. Ling, L. Girnita, O. Buda, G.A. CalinNon-coding RNAs: the cancer genome dark matter that matters Clin Chem Lab Med, 55 (5) (2017), pp. 705-714

4 C. Braicu, A.A. Zimta, A. Harangus, et al.The function of non-coding RNAs in lung cancer tumorigenesis Cancers, 11 (5) (2019), p. 605

5 C. Iaconetti, C. Gareri, A. Polimeni, C. IndolfiNon-coding RNAs: the “dark matter” of cardiovascular pathophysiology Int J Mol Sci, 14 (10) (2013), pp. 19987-20018

6 M.W. Wright, E.A. BrufordNaming 'junk': human non-protein coding RNA (ncRNA) gene nomenclature Hum Genom, 5 (2) (2011), pp. 90-98

7 M. Losko, J. Kotlinowski, J. JuraLong noncoding RNAs in metabolic syndrome related disorders Mediat Inflamm, 2016 (2016), Article 5365209

8 Y. Su, H. Wu, A. Pavlosky, et al.Regulatory non-coding RNA: new instruments in the orchestration of cell death Cell Death Dis, 7 (8) (2016), Article e2333

9 C.M. ArraianoRegulatory noncoding RNAs: functions and applications in health and disease FEBS J, 288 (22) (2021), pp. 6308-6309

10 E. Lekka, J. HallNoncoding RNAs in disease FEBS Lett, 592 (17) (2018), pp. 2884-2900

11 D.K. Soni, R. BiswasRole of non-coding RNAs in post-transcriptional regulation of lung diseases Front Genet, 12 (2021), Article 767348

12 M. Pu, J. Chen, Z. Tao, et al.Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression Cell Mol Life Sci, 76 (3) (2019), pp. 441-451

13 C. Catalanotto, C. Cogoni, G. ZardoMicroRNA in control of gene expression: an overview of nuclear functions Int J Mol Sci, 17 (10) (2016), p. 1712

14 K.K. Ebbesen, J. Kjems, T.B. HansenCircular RNAs: identification, biogenesis and function Biochim Biophys Acta, 1859 (1) (2016), pp. 163-168

15 X. He, C. Ou, Y. Xiao, Q. Han, H. Li, S. ZhouLncRNAs: key players and novel insights into diabetes mellitus Oncotarget, 8 (41) (2017), pp. 71325-71341

16 Z. Li, Z. Zhao, M. Wang, X. ZhouThe Role of Long Noncoding RNAs in Gene Expression Regulation Gene Expression Profiling in Cancer, London IntechOpen (2019), pp. 1-17

17 H. Choquet, D. MeyreMolecular basis of obesity: current status and future prospects Curr Genom, 12 (3) (2011), pp. 154-168

18 J.S.M. Sabir, A. El Omri, B. Banaganapalli, et al.Unraveling the role of salt-sensitivity genes in obesity with integrated network biology and co-expression analysis PLoS One, 15 (2) (2020), Article e0228400

19 N. Pescador, M. Pérez-Barba, J.M. Ibarra, A. Corbatón, M.T. Martínez-Larrad, M. Serrano-RíosSerum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers PLoS One, 8 (10) (2013), Article e77251

20 W. Gallo, J.L.S. Esguerra, L. Eliasson, O. MelandermiR-483-5p associates with obesity and insulin resistance and independently associates with new onset diabetes mellitus and cardiovascular disease PLoS One, 13 (11) (2018), Article e0206974

21 S. Ghorbani, R. Mahdavi, B. Alipoor, et al.Decreased serum microRNA-21 level is associated with obesity in healthy and type 2 diabetic subjects Arch Physiol Biochem, 124 (4) (2018), pp. 300-305

22 H.A. Al-RawafCirculating microRNAs and adipokines as markers of metabolic syndrome in adolescents with obesity Clin Nutr, 38 (5) (2019), pp. 2231-2238

23 X. Cui, L. You, L. Zhu, et al.Change in circulating microRNA profile of obese children indicates future risk of adult diabetes Metabolism, 78 (2018), pp. 95-105

24 C. Castaño, S. Kalko, A. Novials, M. PárrizasObesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice Proc Natl Acad Sci U S A, 115 (48) (2018), pp. 12158-12163

25 R.A. McGregor, M.S. ChoimicroRNAs in the regulation of adipogenesis and obesity Curr Mol Med, 11 (4) (2011), pp. 304-316

26 F. Zhang, D. Ma, W. Zhao, et al.Obesity-induced overexpression of miR-802 impairs insulin transcription and secretion Nat Commun, 11 (1) (2020), p. 1822

27 R.J. Church, G.A. Kullak-Ublick, J. Aubrecht, et al.Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort Hepatology, 69 (2) (2019), pp. 760-773

28 S. Subudhi, H.K. Drescher, L.E. Dichtel, et al.Distinct hepatic gene-expression patterns of NAFLD in patients with obesity Hepatol Commun, 6 (1) (2022), pp. 77-89

29 L. Bonsembiante, G. Targher, C. MaffeisNon-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr, 76 (1) (2022), pp. 28-39

30 Z. Fang, G. Dou, L. WangMicroRNAs in the pathogenesis of nonalcoholic fatty liver disease Int J Biol Sci, 17 (7) (2021), pp. 1851-1863

31 H. Xu, Y. Tian, D. Tang, et al.An endoplasmic reticulum stress-microRNA-26a feedback circuit in NAFLD Hepatology, 73 (4) (2021), pp. 1327-1345

32 M. ZaiouThe emerging role and promise of circular RNAs in obesity and related metabolic disorders Cells, 9 (6) (2020), p. 1473

33 H. Al-Sulaiti, A.S. Dömling, M.A. ElrayessMediators of Impaired Adipogenesis in Obesity-Associated Insulin Resistance and T2DM. Adipose Tissue - an Update IntechOpen (2019), pp. 1-26

34 A. Li, W. Huang, X. Zhang, L. Xie, X. MiaoIdentification and characterization of CircRNAs of two pig breeds as a new biomarker in metabolism-related diseases Cell Physiol Biochem, 47 (6) (2018), pp. 2458-2470

35 C. Arcinas, W. Tan, W. Fang, et al.Adipose circular RNAs exhibit dynamic regulation in obesity and functional role in adipogenesis Nat Metab, 1 (7) (2019), pp. 688-703

36 W. Sun, X. Sun, W. Chu, S. Yu, F. Dong, G. XuCircRNA expression profiles in human visceral preadipocytes and adipocytes Mol Med Rep, 21 (2) (2020), pp. 815-821

37 Y. Liu, H. Liu, Y. Li, et al.Circular RNA SAMD4A controls adipogenesis in obesity through the miR-138-5p/EZH2 axis Theranostics, 10 (10) (2020), pp. 4705-4719

38 J. Sun, Y. Ruan, M. Wang, et al.Differentially expressed circulating LncRNAs and mRNA identified by microarray analysis in obese patients Sci Rep, 6 (2016), Article 35421

39 B. Xu, I. Gerin, H. Miao, et al.Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity PLoS One, 5 (12) (2010), Article e14199

40 X. Zhang, C. Xue, J. Lin, et al.Interrogation of nonconserved human adipose lincRNAs identifies a regulatory role of linc-ADAL in adipocyte metabolism Sci Transl Med, 10 (446) (2018), Article eaar5987

41 A. Nowak, C. Kobierzycki, P. DziegielThe Role of leptin in pathogenesis of obesity-related cancers Postepy Biol Komorki, 42 (2) (2015), pp. 309-328

42 A.G. Izquierdo, A.B. Crujeiras, F.F. Casanueva, M.C. CarreiraLeptin, obesity, and leptin resistance: where are we 25 years later? Nutrients, 11 (11) (2019), p. 2704

43 K.A. Lo, S. Huang, A.C.E. Walet, et al.Adipocyte long-noncoding RNA transcriptome analysis of obese mice identified lnc-leptin, which regulates leptin Diabetes, 67 (6) (2018), pp. 1045-1056

44 F.F. Zhang, Y.H. Liu, D.W. Wang, et al.Obesity-induced reduced expression of the lncRNA ROIT impairs insulin transcription by downregulation of Nkx 6.1 methylation Diabetologia, 63 (4) (2020), pp. 811-824

45 Y. Liu, Y. Ji, M. Li, et al.Integrated analysis of long noncoding RNA and mRNA expression profile in children with obesity by microarray analysis Sci Rep, 8 (1) (2018), p. 8750

46 C. Esau, S. Davis, S.F. Murray, et al.miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting Cell Metabol, 3 (2) (2006), pp. 87-98

47 X. Wang, Y. He, B. Mackowiak, B. GaoMicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases Gut, 70 (4) (2021), pp. 784-795

48 Y. He, R.M. Rodrigues, X. Wang, et al.Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis J Clin Invest, 131 (3) (2021), pp. 141513-151415

49 R. Natarajan, S. Putta, M. KatoMicroRNAs and diabetic complications J Cardiovasc Transl Res, 5 (4) (2012), pp. 413-141549

50 R. Jiménez-Lucena, A. Camargo, J.F. Alcalá-Diaz, et al.A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study Exp Mol Med, 50 (12) (2018), pp. 1-12

51 R. Jiménez-Lucena, O.A. Rangel-Zúñiga, J.F. Alcalá-Díaz, et al.Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study Mol Ther Nucleic Acids, 12 (2018), pp. 146-157

52 H.A. Al-Muhtaresh, G. Al-KafajiEvaluation of two-diabetes related microRNAs suitability as earlier blood biomarkers for detecting prediabetes and type 2 diabetes mellitus J Clin Med, 7 (2) (2018), p. 12

53 X. Deng, Y. Liu, M. Luo, et al.Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus Oncotarget, 8 (38) (2017), pp. 63038-63046

54 A. Jaeger, L. Zollinger, C.H. Saely, et al.Circulating microRNAs-192 and-194 are associated with the presence and incidence of diabetes mellitus Sci Rep, 8 (1) (2018), Article 14274

55 M. Witkowski, A. Weithauser, T. Tabaraie, et al.Micro-RNA-126 reduces the blood thrombogenicity in diabetes mellitus via targeting of tissue factor Arterioscler Thromb Vasc Biol, 36 (6) (2016), pp. 1263-1271

56 A. Giannella, C.M. Radu, L. Franco, et al.Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance Cardiovasc Diabetol, 16 (1) (2017), p. 118

57 E.Ł. Stępień, M. Durak-Kozica, A. Kamińska, et al.Circulating ectosomes: determination of angiogenic microRNAs in type 2 diabetes Theranostics, 8 (14) (2018), pp. 3874-3890

58 J. Dooley, J.E. Garcia-Perez, J. Sreenivasan, et al.The microRNA-29 family dictates the balance between homeostatic and pathological glucose handling in diabetes and obesity Diabetes, 65 (1) (2016), pp. 53-61

59 E. Satake, M.G. Pezzolesi, Z.I. Md Dom, A.M. Smiles, M.A. Niewczas, A.S. KrolewskiCirculating miRNA profiles associated with hyperglycemia in patients with type 1 diabetes Diabetes, 67 (5) (2018), pp. 1013-1023

60 J.W. Kornfeld, C. Baitzel, A.C. Könner, et al.Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b Nature, 494 (7435) (2013), pp. 111-115

61 C. Zhao, J. Dong, T. Jiang, et al.Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus PLoS One, 6 (8) (2011), Article e23925

62 C.V. Collares, A.F. Evangelista, D.J. Xavier, et al.Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients BMC Res Notes, 6 (2013), p. 491

63 A. Regmi, G. Liu, X. Zhong, et al.Evaluation of serum microRNAs in patients with diabetic kidney disease: a nested case-controlled study and bioinformatics analysis Med Sci Mon Int Med J Exp Clin Res, 25 (2019), pp. 1699-1708

64 L. Pan, W. Lian, X. Zhang, et al.Human circular RNA-0054633 regulates high glucose-induced vascular endothelial cell dysfunction through the microRNA-218/roundabout 1 and microRNA-218/heme oxygenase-1 axes Int J Mol Med, 42 (1) (2018), pp. 597-606

65 H. Wu, S. Wu, Y. Zhu, et al.Hsa_circRNA_0054633 is highly expressed in gestational diabetes mellitus and closely related to glycosylation index Clin Epigenet, 11 (1) (2019), p. 22

66 Z. Zhao, X. Li, D. Jian, P. Hao, L. Rao, M. LiHsa_circ_0054633 in peripheral blood can be used as a diagnostic biomarker of pre-diabetes and type 2 diabetes mellitus Acta Diabetol, 54 (3) (2017), pp. 237-245

67 G. Haddad, J.M. LorenzenBiogenesis and function of circular RNAs in health and in disease Front Pharmacol, 10 (2019), p. 428

68 S. Haque, R.M. Ames, K. Moore, B.P. Lee, N. Jeffery, L.W. HarriesIslet-expressed circular RNAs are associated with type 2 diabetes status in human primary islets and in peripheral blood BMC Med Genom, 13 (1) (2020), p. 64

69 Y. Fang, X. Wang, W. Li, et al.Screening of circular RNAs and validation of circANKRD36 associated with inflammation in patients with type 2 diabetes mellitus Int J Mol Med, 42 (4) (2018), pp. 1865-1874

70 W. Hu, Q. Han, L. Zhao, L. WangCircular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR-185/TGF-β1 J Cell Physiol, 234 (2) (2019), pp. 1469-1476

71 G. Carter, B. Miladinovic, A.A. Patel, L. Deland, S. Mastorides, N.A. PatelCirculating long noncoding RNA GAS5 levels are correlated to prevalence of type 2 diabetes mellitus BBA Clin, 4 (2015), pp. 102-107

72 X. Ge, B. Xu, W. Xu, et al.Long noncoding RNA GAS5 inhibits cell proliferation and fibrosis in diabetic nephropathy by sponging miR-221 and modulating SIRT1 expression Aging (Albany NY), 11 (20) (2019), pp. 8745-8759

73 X. Li, L. Zeng, C. Cao, et al.Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy Exp Cell Res, 350 (2) (2017), pp. 327-335

74 L.E. Abdulle, J.L. Hao, O.P. Pant, et al.MALAT1 as a diagnostic and therapeutic target in diabetes-related complications: a promising long-noncoding RNA Int J Med Sci, 16 (4) (2019), pp. 548-555

75 S. Jo, J. Chen, G. Xu, T.B. Grayson, L.A. Thielen, A. ShalevmiR-204 controls glucagon-like peptide 1 receptor expression and agonist function Diabetes, 67 (2) (2018), pp. 256-264

76 X. Fu, L. Jin, X. Wang, et al.MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation Proc Natl Acad Sci U S A, 110 (44) (2013), pp. 17892-17897

77 X. Fu, B. Dong, Y. Tian, et al.MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids J Clin Invest, 125 (6) (2015), pp. 2497-2509

78 H. Xu, X. Du, J. Xu, et al.Pancreatic β cell microRNA-26a alleviates type 2 diabetes by improving peripheral insulin sensitivity and preserving β cell function PLoS Biol, 18 (2) (2020), Article e3000603

79 Y. Gu, G. Ke, L. Wang, E. Zhou, K. Zhu, Y. WeiAltered expression profile of circular RNAs in the serum of patients with diabetic retinopathy revealed by microarray Ophthalmic Res, 58 (3) (2017), pp. 176-184

80 Z. Zhang, W. Gao, Q.Q. Long, et al.Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population Sci Rep, 7 (1) (2017), p. 7491

81 P. Marchetti, M. Bugliani, V. De Tata, M. Suleiman, L. MarselliPancreatic beta cell identity in humans and the role of type 2 diabetes Front Cell Dev Biol, 5 (2017), p. 55

82 N. Alimoradi, N. Firouzabadi, R. FatehiMetformin and insulin-resistant related diseases: emphasis on the role of microRNAs Biomed Pharmacother, 139 (2021), Article 111662

83 D. Skuratovskaia, M. Vulf, A. Komar, E. Kirienkova, L. LitvinovaPromising directions in atherosclerosis treatment based on epigenetic regulation using microRNAs and long noncoding RNAs Biomolecules, 9 (6) (2019), p. 226

84 Y. Jiang, D. Sun-Waterhouse, Y. Chen, F. Li, D. LiEpigenetic mechanisms underlying the benefits of flavonoids in cardiovascular health and diseases: are long non-coding RNAs rising stars? Crit Rev Food Sci Nutr, 62 (14) (2022), pp. 3855-3872

85 D.L. Michell, K.C. VickersHDL and microRNA therapeutics in cardiovascular disease Pharmacol Ther, 168 (2016), pp. 43-52

86 R.S. Gangwar, S. Rajagopalan, R. Natarajan, J.A. DeiuliisNoncoding RNAs in cardiovascular disease: pathological relevance and emerging role as biomarkers and therapeutics Am J Hypertens, 31 (2) (2018), pp. 150-165

87 Q.J. Tang, H.P. Lei, H. Wu, et al.Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy Acta Pharmacol Sin, 40 (2) (2019), pp. 208-215

88 C. Widera, S.K. Gupta, J.M. Lorenzen, et al.Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome J Mol Cell Cardiol, 51 (5) (2011), pp. 872-875

89 E. Cavarretta, G. FratiMicroRNAs in coronary heart disease: ready to enter the clinical arena? BioMed Res Int, 2016 (2016), Article 2150763

90 R. Navickas, D. Gal, A. Laucevičius, A. Taparauskaitė, M. Zdanytė, P. HolvoetIdentifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review Cardiovasc Res, 111 (4) (2016), pp. 322-337

91 M. Karakas, C. Schulte, S. Appelbaum, et al.Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study Eur Heart J, 38 (7) (2017), pp. 516-523

92 D. Kaudewitz, A. Zampetaki, M. MayrMicroRNA biomarkers for coronary artery disease? Curr Atherosclerosis Rep, 17 (12) (2015), p. 70

93 Y.L. Wang, W. YuAssociation of circulating microRNA-122 with presence and severity of atherosclerotic lesions PeerJ, 6 (2018), Article e5218

94 F. Jansen, X. Yang, S. Proebsting, et al.MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease J Am Heart Assoc, 3 (6) (2014), Article e001249

95 J. Wang, Y. Pei, Y. Zhong, S. Jiang, J. Shao, J. GongAltered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease PLoS One, 9 (9) (2014), Article e107012

96 T. Jakobi, D. Siede, J. Eschenbach, et al.Deep characterization of circular RNAs from human cardiovascular cell models and cardiac tissue Cells, 9 (7) (2020), p. 1616

97 L.M. Holdt, A. Stahringer, K. Sass, et al.Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans Nat Commun, 7 (2016), Article 12429

98 H.H. Geng, R. Li, Y.M. Su, et al.The circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR-7a on its target genes expression PLoS One, 11 (3) (2016), Article e0151753

99 Z. Zhao, X. Li, C. Gao, et al.Peripheral blood circular RNA hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease Sci Rep, 7 (2017), Article 39918

100 T. Wu, D. Wu, Q. Wu, et al.Knockdown of long non-coding RNA-ZFAS1 protects cardiomyocytes against acute myocardial infarction via anti-apoptosis by regulating miR-150/CRP J Cell Biochem, 118 (10) (2017), pp. 3281-3289

101 T. Josefs, R.A. BoonThe long non-coding road to atherosclerosis Curr Atherosclerosis Rep, 22 (10) (2020), p. 55

102 H. Li, S. Han, Q. Sun, et al.Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression Aging (Albany NY), 11 (6) (2019), pp. 1695-1715

103 Z. Liu, P. Ye, S. Wang, et al.MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction Circ Cardiovasc Genet, 8 (1) (2015), pp. 11-20

104 K. Theodorou, R.A. BoonEndothelial cell metabolism in atherosclerosis Front Cell Dev Biol, 6 (2018), p. 82

105 M.W. Feinberg, K.J. MooreMicroRNA regulation of atherosclerosis Circ Res, 118 (4) (2016), pp. 703-720

106 S. Meiler, Y. Baumer, E. Toulmin, K. Seng, W.A. BoisvertMicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis Arterioscler Thromb Vasc Biol, 35 (2) (2015), pp. 323-331

107 X.D. Meng, H.H. Yao, L.M. Wang, et al.Knockdown of GAS5 inhibits atherosclerosis progression via reducing EZH2-mediated ABCA1 transcription in ApoE-/- mice Mol Ther Nucleic Acids, 19 (2020), pp. 84-96

108 J.X. PanLncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway Eur Rev Med Pharmacol Sci, 21 (2) (2017), pp. 322-328

109 Y. Zhuang, T. Li, H. Xiao, et al.LncRNA-H19 drives cardiomyocyte senescence by targeting miR-19a/socs 1/p53 axis Front Pharmacol, 12 (2021), Article 631835

110 P. Ranasinghe, Y. Mathangasinghe, R. Jayawardena, A.P. Hills, A. MisraPrevalence and trends of metabolic syndrome among adults in the Asia-Pacific region: a systematic review BMC Publ Health, 17 (1) (2017), p. 101

111 P. Willeit, P. Skroblin, A.R. Moschen, et al.Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes Diabetes, 66 (2) (2017), pp. 347-357

112 Y. Meng, A. Eirin, X.Y. Zhu, et al.Micro-RNAS regulate metabolic syndrome-induced senescence in porcine adipose tissue-derived mesenchymal stem cells through the P16/MAPK pathway Cell Transplant, 27 (10) (2018), pp. 1495-1503

113 P. Goguet-Rubio, R.L. Klug, D.L. Sharma, et al.Existence of a strong correlation of biomarkers and miRNA in females with metabolic syndrome and obesity in a population of West Virginia Int J Med Sci, 14 (6) (2017), pp. 543-553

114 D.S. Karolina, S. Tavintharan, A. Armugam, et al.Circulating miRNA profiles in patients with metabolic syndrome J Clin Endocrinol Metab, 97 (12) (2012), pp. E2271-E2276

115 D. Nasias, I. Evangelakos, V. Nidris, et al.Significant changes in hepatic transcriptome and circulating miRNAs are associated with diet-induced metabolic syndrome in apoE3L.CETP mice J Cell Physiol, 234 (11) (2019), pp. 20485-20500

116 M. Bakr Zaki, A.I. Abulsoud, A.M. Elsisi, et al.Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients Diabetes Metab Syndr Obes, 12 (2019), pp. 601-611

117 F. Ramzan, R.F. D'Souza, B.R. Durainayagam, et al.Circulatory miRNA biomarkers of metabolic syndrome Acta Diabetol, 57 (2) (2020), pp. 203-214

118 Y.T. Wang, P.C. Tsai, Y.C. Liao, C.Y. Hsu, S.H.H. JuoCirculating microRNAs have a sex-specific association with metabolic syndrome J Biomed Sci, 20 (1) (2013), p. 72

119 G. Liu, Y. Lei, S. Luo, et al.MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome Bioengineered, 12 (1) (2021), pp. 3864-3872

120 Y. Zhu, W. Gui, X. Lin, H. LiKnock-down of circular RNA H19 induces human adipose-derived stem cells adipogenic differentiation via a mechanism involving the polypyrimidine tract-binding protein 1 Exp Cell Res, 387 (2) (2020), Article 111753

121 D. Yao, Z. Lin, X. Zhan, X. ZhanIdentifying potential functional lncRNAs in metabolic syndrome by constructing a lncRNA-miRNA-mRNA network J Hum Genet, 65 (11) (2020), pp. 927-938

122 L. Xihua, T. Shengjie, G. Weiwei, et al.Circulating miR-143-3p inhibition protects against insulin resistance in Metabolic Syndrome via targeting of the insulin-like growth factor 2 receptor Transl Res, 205 (2019), pp. 33-43

123 K.J. Rayner, C.C. Esau, F.N. Hussain, et al.Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides Nature, 478 (7369) (2011), pp. 404-407

124 V. Rottiers, A.M. NäärMicroRNAs in metabolism and metabolic disorders Nat Rev Mol Cell Biol, 13 (4) (2012), pp. 239-250

125 M. Winkle, S.M. El-Daly, M. Fabbri, G.A. CalinNoncoding RNA therapeutics - challenges and potential solutions Nat Rev Drug Discov, 20 (8) (2021), pp. 629-651

126 J. Baek, S. Kang, H. MinMicroRNA-targeting therapeutics for hepatitis C Arch Pharm Res (Seoul), 37 (3) (2014), pp. 299-305

127 M. Takahashi, S.P. Han, L.J. Scherer, S. Yoon, J.J. RossiCurrent Progress and Future Prospects in Nucleic Acid Based Therapeutics. Comprehensive Medicinal Chemistry III Elsevier, Amsterdam (2017), pp. 280-313

128 M.S. Beg, A.J. Brenner, J. Sachdev, et al.Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Invest N Drugs, 35 (2) (2017), pp. 180-188

129 S. Roy, C. Trautwein, T. Luedde, C. RoderburgA general overview on non-coding RNA-based diagnostic and therapeutic approaches for liver diseases Front Pharmacol, 9 (2018), p. 805

130 V. Baumann, J. WinklermiRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents Future Med Chem, 6 (17) (2014), pp. 1967-1984

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Comprehensive biological function analysis of lncRNAs in hepatocellular carcinoma

DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects

Breaking paradigms: Long non-coding RNAs forming gene fusions with potential implications in cancer

Long noncoding RNA (lncRNA) H19: An essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseases

Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases